Get started
Author

Kris F. Sachsenmeier

Observed names: K F Sachsenmeier, K. Sachsenmeier, Kris F Sachsenmeier, Kris Sachsenmeier, Sachsenmeier, Kris
ORCID: 0000-0002-5081-8885
Observed ORCID: 0000-0002-5081-8885
OpenAlex ID: A5044997582
Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses
2016 · Arabella Young, Shin Foong Ngiow, et al. · Cancer Cell · 400
PDF
A New Bliss Independence Model to Analyze Drug Combination Data
2014 · Wei Zhao, Kris Sachsenmeier, et al. · SLAS DISCOVERY · 332
PDF
Targeting CD73 in the tumor microenvironment with MEDI9447
2016 · Carl M. Hay, Erin Sult, et al. · OncoImmunology · 302
Improving target cell specificity using a novel monovalent bispecific IgG design
2015 · Yariv Mazor, Vaheh Oganesyan, et al. · mAbs · 152
CD73 Regulates Stemness and Epithelial-Mesenchymal Transition in Ovarian Cancer-Initiating Cells
2018 · Michela Lupia, Francesca Angiolini, et al. · Stem Cell Reports · 138
PDF
Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence
2017 · Yariv Mazor, Kris F. Sachsenmeier, et al. · Scientific Reports · 132
PDF
Inhibition of CD73 AMP hydrolysis by a therapeutic antibody with a dual, non-competitive mechanism of action
2016 · James C. Geoghegan, Gundo Diedrich, et al. · mAbs · 121
PDF
Small molecule AZD4635 inhibitor of A2AR signaling rescues immune cell function including CD103+ dendritic cells enhancing anti-tumor immunity
2020 · Alexandra Borodovsky, Christine M Barbon, et al. · Journal for ImmunoTherapy of Cancer · 109
Adenosine Signaling Is Prognostic for Cancer Outcome and Has Predictive Utility for Immunotherapeutic Response
2020 · Ben Sidders, Pei Zhang, et al. · Clinical Cancer Research · 104
Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors
2022 · Emerson A. Lim, Johanna C. Bendell, et al. · Clinical Cancer Research · 96
Switching off CD73: a way to boost the activity of conventional and targeted antineoplastic therapies
2017 · Luca Antonioli, Sergey V. Novitskiy, et al. · Drug Discovery Today · 77
Combining phenotypic and proteomic approaches to identify membrane targets in a ‘triple negative’ breast cancer cell type
2013 · Steven Rust, Sandrine Guillard, et al. · Molecular Cancer · 57
PDF
Identification of anti-tumour biologics using primary tumour models, 3-D phenotypic screening and image-based multi-parametric profiling
2015 · Alan M. Sandercock, Steven Rust, et al. · Molecular Cancer · 54
PDF
RAS oncogenic activity predicts response to chemotherapy and outcome in lung adenocarcinoma
2022 · Philip East, Gavin P. Kelly, et al. · Nature Communications · 42
PDF
Transforming Growth Factor-β1 Inhibits Nucleosomal Fragmentation in Human Keratinocytes following Loss of Adhesion
1996 · Kris F. Sachsenmeier, Nader Sheibani, et al. · Journal of Biological Chemistry · 34
PDF
Selective activation of anti-CD73 mechanisms in control of primary tumors and metastases
2017 · Dipti Vijayan, Deborah S. Barkauskas, et al. · OncoImmunology · 30
PDF
Inhibition of Rb and p53 Is Insufficient for SV40 T-Antigen Transformation
2001 · Kris F. Sachsenmeier, James M. Pipas · Virology · 29
PDF
Abstract CT026: Evidence of immune activation in the first-in-human Phase Ia dose escalation study of the adenosine 2a receptor antagonist, AZD4635, in patients with advanced solid tumors
2019 · Johanna Bendell, Todd Bauer, et al. · Cancer Research · 27
Abstract 5580: Preclinical pharmacodynamics and antitumor activity of AZD4635, a novel adenosine 2A receptor inhibitor that reverses adenosine mediated T cell suppression
2017 · Alexandra Borodovsky, Yanjun Wang, et al. · Cancer Research · 26
A phase I, open-label, multicenter study to assess the safety, pharmacokinetics, and preliminary antitumor activity of AZD4635 both as monotherapy and in combination in patients with advanced solid malignancies: Results from prostate cancer patients (NCT02740985).
2020 · Emerson A. Lim, Todd Michael Bauer, et al. · Journal of Clinical Oncology · 25
OA07.08 HUDSON: An Open-Label, Multi-Drug, Biomarker-Directed, Phase II Platform Study in Patients with NSCLC, who Progressed on Anti-PD(L)1 Therapy
2021 · B. Besse, M. Awad, et al. · Journal of Thoracic Oncology · 23
First-in-human study of AZD5153, a small molecule inhibitor of bromodomain protein 4 (BRD4), in patients (pts) with relapsed/refractory (RR) malignant solid tumor and lymphoma: Preliminary data.
2019 · Judy Sing-Zan Wang, Serena De Vita, et al. · Journal of Clinical Oncology · 23
Development of a Novel Ectonucleotidase Assay Suitable for High-Throughput Screening
2012 · Kris F. Sachsenmeier, Carl Hay, et al. · SLAS DISCOVERY · 23
Evaluation of Combination Strategies for the A2AR Inhibitor AZD4635 Across Tumor Microenvironment Conditions via a Systems Pharmacology Model
2021 · Veronika Voronova, Kirill Peskov, et al. · Frontiers in Immunology · 20
PDF
Propagation of Wild-Type and Mutant SV40
2003 · James D. Tremblay, Kris F. Sachsenmeier, et al. · Humana Press eBooks · 18
Works count: 94
Citation count: 2,550
H-index: 23
I10-index: 32
Year
Topic
Type